Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (MAMBO) Phase I
Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (The MAMBO Study) Phase I
Hospital Universitari Vall d'Hebron Research Institute
108 participants
Jan 25, 2024
OBSERVATIONAL
Conditions
Summary
The goal of this observational study is to identify differential traits in spontaneous migraine attacks that can help us predict the response to treatment with sumatriptan. Participants will be asked to register the headache characteristics before and after taking sumatriptan and whether the treatment was effective or not during four migraine attacks.
Eligibility
Inclusion Criteria5
- Migraine with or without aura diagnosis according to ICHD-3 criteria
- \<8 migraine days per month
- Be able to read, write and understand instructions.
- Have internet access and mail address
- Signing of the informed consent
Exclusion Criteria7
- Active preventive treatment for migraine
- Active medication with an effect over the central nervous system
- Serious physical or psychiatric condition
- Cardiovascular or hepatic disease
- Pregnant or breastfeeding women
- Any triptan contraindication
- Severe migraine attacks without previous response to triptans or NSAIDs
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Register the response to treatment and headache characteristics.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06503848